Schoenberg Mark 4
4 · UroGen Pharma Ltd. · Filed Sep 9, 2025
Insider Transaction Report
Form 4
Schoenberg Mark
Chief Medical Officer
Transactions
- Sale
Ordinary Shares
2025-09-08$19.11/sh−871$16,645→ 149,025 total - Exercise/Conversion
Ordinary Shares
2025-09-07+1,667→ 149,896 total - Exercise/Conversion
Restricted Stock Units
2025-09-07−1,667→ 1,667 total→ Ordinary Shares (1,667 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- [F2]Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- [F3]The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.